semiconductor sequencing

The startup is developing a semiconductor chip for single-molecule sequencing and plans to make the technology available to early-access customers by the end of this year.

At the JP Morgan Healthcare conference, Illumina unveiled the semiconductor-based sequencing system it has been developing as part of its Firefly project.

Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance. 

Earlier this month at AGBT, company researchers presented the new developments, which Thermo Fisher plans to roll out later this year.

Illumina's CEO described the one-channel chemistry behind Firefly, saying that its simplicity would allow it to be deployed into new markets, including hospitals.

The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.

The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.

NEW YORK (GenomeWeb News) – Privately held Chinese diagnostics services firm iGenomics has purchased 17 of Life Technologies' Ion Proton next-generation sequencing systems and has agreed to add 15 more machines by the end of the year, Life Tech said today.

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today issued a statement disputing remarks made by Illumina CEO Jay Flatley at an investment conference about his firm's relationship with Oxford.

NEW YORK (GenomeWeb News) – Life Technologies today announced its participation in the Stratified Medicine Scotland Innovation Centre, or SMS-IC, a collaboration among academic, industrial, and the UK's National Health Service community to create a stratified medicine research infrastructure.

Pages

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.